With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct strengths and limitations. IV administration offers established dosing precision, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results